Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells
Abstract Cancer cells exhibit altered metabolism, a phenomenon described a century ago by Otto Warburg. However, metabolic drug targeting is considered an underutilized and poorly understood area of cancer therapy. Metformin, a metabolic drug commonly used to treat type 2 diabetes, has been associat...
Main Authors: | Abdelnour H. Alhourani, Tia R. Tidwell, Ansooya A. Bokil, Gro V. Røsland, Karl Johan Tronstad, Kjetil Søreide, Hanne R. Hagland |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-89861-6 |
Similar Items
-
Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- and gene-specific scoring alternatives on recommended multi-gene panels.
by: Marianne Berg, et al.
Published: (2014-01-01) -
Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots
by: Martin M Watson, et al.
Published: (2019-12-01) -
Genetic and Epigenetic Traits as Biomarkers in Colorectal Cancer
by: Marianne Berg, et al.
Published: (2011-12-01) -
Metformin and Colorectal Cancer
by: Takuma Higurashi, et al.
Published: (2018-10-01) -
Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II
by: Yaodu Wang, et al.
Published: (2017-01-01)